Epcoritamab for post-transplant lymphoma that didn't respond to treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have PTLD that came back or didn't respond to treatment after a solid organ transplant (like kidney, liver, heart, or lung).
- You must have tried and not responded to rituximab (a common antibody therapy) or a chemo regimen, and your immunosuppression medication was reduced without success.
- Your cancer must be measurable on a scan (at least 1.5 cm) or in your bone marrow.
- Your blood counts, kidney and liver function need to be within certain ranges (your doctor will check).
- You cannot have PTLD in your brain or spinal cord, active hepatitis B or C, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of two immunotherapy drugs (loncastuximab tesirine and rituximab) to treat a type of lymphoma (blood cancer) that develops after solid organ transplantation. The goal is to see if this treatment can help control the cancer while being safe for transplant patients.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Hear when a new Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.